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The transmembrane glycoprotein E11 is considered critical in early osteoblast–osteocyte transitions (osteocytogenesis), however its
function and regulatory mechanisms are still unknown. Using the late osteoblast MLO-A5 cell line we reveal increased E11 protein/mRNA
expression (P< 0.001) concomitant with extensive osteocyte dendrite formation and matrix mineralization (P< 0.001). Transfection with
E11 significantly increased mRNA levels (P< 0.001), but immunoblotting failed to detect any correlative increases in E11 protein levels,
suggestive of post-translational degradation. We found that exogenous treatment of MLO-A5 and osteocytic IDG-SW3 cells with 10mM
ALLN (calpain and proteasome inhibitor) stabilized E11 protein levels and induced a profound increase in osteocytic dendrite formation
(P< 0.001). Treatment with other calpain inhibitors failed to promote similar osteocytogenic changes, suggesting that these effects of
ALLN rely upon its proteasome inhibitor actions. Accordingly we found that proteasome-selective inhibitors (MG132/lactacystin/
Bortezomib/Withaferin-A) produced similar dose-dependent increases in E11 protein levels in MLO-A5 and primary osteoblast cells. This
proteasomal targeting was confirmed by immunoprecipitation of ubiquitinylated proteins, which included E11, and by increased levels of
ubiquitinylated E11 protein upon addition of the proteasome inhibitors MG132/Bortezomib. Activation of RhoA, the small GTPase, was
found to be increased concomitant with the peak in E11 levels and its downstream signaling was also observed to promote MLO-A5 cell
dendrite formation. Our data indicate that a mechanism reliant upon blockade of proteasome-mediated E11 destabilization contributes to
osteocytogenesis and that this may involve downstream targeting of RhoA. This work adds to our mechanistic understanding of the factors
regulating bone homeostasis, which may lead to future therapeutic approaches.
J. Cell. Physiol. 9999: 1–13, 2015.  2015 The Authors. Journal of Cellular Physiology published by Wiley Periodicals, Inc.
The terminally-differentiated, osteoblast-derived osteocytes are
the most numerous of all the cells within bone and are essential
to bone structure and function (Dallas et al., 2013). Most original
paradigms had proposed that osteocytes are passive in their
formation (Skerry et al., 1989; Nefussi et al., 1991; Palumbo
et al., 2004). Recent evidence, however, now indicates that initial
“embedding” involves their active contributionwith vital genetic
and dramatic morphological transformations; not simply
entrapment of defunct osteoblasts (Holmbeck et al., 2005).
Along with concomitant dendrite formation, this creates bone’s
osteocyte-canalicular network, which is now known to
orchestrate bone remodelling (Bonewald, 2002, 2007, 2012).
Compelling evidence for this “orchestrator” function comes
from the discovery that osteocytes, deep in calcified bone,
produce sclerostin, a Wnt inhibitor and potent negative
modulator of bone formation (Balemans et al., 2001; Li et al.,
2009; Staines et al., 2012b). Furthermore, it has been more
recently shown that osteocytes can also communicate with
bone-resorbing osteoclast cells through RANKL expression
(Nakashima and Takayanagi, 2011; Xiong et al., 2011).
Although it is well known that osteocytes are derived from
osteoblasts, the mechanisms which govern this transition
(osteocytogenesis) are yet to be elucidated. Many different
genes have been suggested to influence osteocytogenesis, one
of which encodes for the transmembrane glycoprotein E11.
Although specific for osteocytes in bone, E11 is also widely
expressed in many tissues throughout the body, such as the
kidney and lung. It therefore has several names (podoplanin,
gp38, T1 alpha, OTS-8 among others) depending on its location
and the species from which it was first isolated. E11 was the
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name given to the protein isolated from rat osteocytes by
Wetterwald et al., (Wetterwald et al., 1996) and is therefore the
common name used to describe this protein in relation to bone.
The protein itself is a hydrophobic, mucin-like, transmembrane
glycoprotein, which can undergo post-translationalmodification
(via O-glycosylation) leading to the production of different
glycoforms. E11 is up-regulated by hypoxia in the lung (Cao
et al., 2003); IL-3 and PROX-1 in the lymphatic system (Hong
et al., 2002; Groger et al., 2004) and TGF-b in fibrosarcoma cells
(Suzuki et al., 2005). The localisation of E11 in early embedding-
osteocytes identified it as a factor which likely contributes
during the vital, early stages of osteocyte differentiation (Nefussi
et al., 1991; Barragan-Adjemian et al., 2006; Zhang et al., 2006).
However, few studies have been performed to investigate the
functions of E11 in osteocytes. It is known that E11 mRNA
expression in osteocytes is up-regulated in response to
mechanical strain in vivo (Zhang et al., 2006). It has also been
shown that the growth of cytoplasmic processes, which is
induced by fluid-flow in MLO-Y4 cells, is abrogated in cells
pre-treated with siRNA targeted against E11 (Zhang et al.,
2006). Over-expression of E11 in ROS 17/2.6 osteoblast-like
cells led to the formation of long processes potentially via
activation of the small GTPase, RhoA which acts through its
downstream effector kinase ROCK to phosphorylate ezrin/
moesin/radixin (ERM) and influence the actin cytoskeleton
(Sprague et al., 1996; Martin-Villar et al., 2006, 2014). These
data, when taken collectively, suggest a key role for E11 in
regulating the cytoskeletal changes associated with process
formation and elongation. As the formation of such processes is
a key feature of a differentiating osteocyte, this suggests an
important functional role for the regulation of E11 during this
mechanism, one which requires further examination.
In this study we have investigated the expression and
regulation of E11 during osteocytogenesis. We found that E11
levels are regulated post-translationally by proteasome
degradation and that their preservation, by inhibition of this
degradation, leads to the induction of an osteocyte-like
morphology in MLO-A5 pre-osteocytic cells, indicating the
importance of E11 during osteocyte differentiation.
Materials and Methods
Animals
C57/BL6 mice were used in all experiments and kept in
polypropylene cages, with light/dark 12-h cycles, at 21 2°C, and
fed ad libitum with maintenance diet (Special Diet Services,
Witham, UK). All experimental protocols were approved by
Roslin Institute’s Animal Users Committee and the animals were
maintained in accordance with UK Home Office guidelines for the
care and use of laboratory animals.
Immunohistochemistry
Tibiae were dissected, fixed in 4% paraformaldehyde (PFA) for
24 h before being decalcified in 10% ethylenediaminetetraacetic
acid (EDTA) pH 7.4 for approximately 3 weeks at 4°C with regular
changes. Tissues were dehydrated and embedded in paraffin wax,
using standard procedures, after which they were sectioned at
6mm. For immunohistochemical analysis, sections were dewaxed
in xylene and rehydrated. Sections were incubated at 37°C for
30min in 1mg/ml trypsin for antigen demasking. Endogenous
peroxidases were blocked by treatment with 3% H2O2 in
methanol (Sigma, Dorset UK). E11 antibodies (R&D systems,
Oxford UK) were used at a dilution of 1/100, and sclerostin
antibodies (R&D systems) at 1/200with appropriate controls used.
The Vectastain ABC universal kit (Vector Laboratories,
Peterborough) was used according to the manufacturer’s
instructions. The sections were dehydrated, counterstained with
haematoxylin and mounted in DePeX.
Primary osteoblast isolation
Primary calvarial osteoblasts were obtained from 4-day-old
C57Bl/6 mice by sequential enzyme digestion of excised calvarial
bones using a four-step process as has previously been described
(Staines et al., 2013; Orriss et al., 2014) [1mg/ml collagenase type II
in Hanks’ balanced salt solution (HBSS) for 10min; 1mg/ml
collagenase type II in HBSS for 30min; 4mM EDTA for 10min;
1mg/ml collagenase type II in HBSS for 30min]. The first digest was
discarded and the cells were re-suspended in growth medium
consisting of a-MEM (Invitrogen, Paisley UK) supplemented with
10% (v/v) FCS (Invitrogen) and 1% gentamycin (Invitrogen).
Osteoblasts were seeded at a density of 1 104 cells/cm2 and
grown to confluency before being administered with proteasome
inhibitors.
MLO-A5 cell culture
The murine MLO-A5 pre-osteocyte cell line was obtained from
Dr. Lynda Bonewald (University of Missouri-Kansas City). Cells
were plated at 35 103 cells/cm2 in multi-well plates and cultured
in a-MEM medium supplemented with 5% (v/v) FBS, 5% (v/v) calf
serum (Invitrogen) and 50mg/ml gentamicin (Invitrogen) at 37°C
with 5% CO2. At confluence (day 0), the medium was changed to
a-MEM supplemented with 10% (v/v) FBS, 50mg/ml gentamicin,
5mM b-glycerol 2-phosphate disodium salt hydrate (bGP, Sigma)
and 100mg/ml ascorbic acid (Sigma) in order to promote
differentiation and matrix mineralization. The MLO-A5 cells were
incubated at 37°C in a humidified atmosphere containing 5% CO2
and the medium was changed every 2–3 days.
ATDC5 cell culture
Chondrogenic murine ATDC5 cells (RIKEN cell bank, Ibaraki,
Japan) were utilized as a well-established model of chondrocyte
matrix mineralization with previous studies detailing their
chondrogenic differentiation and subsequent mineralization
(Newton et al., 2012; Staines et al., 2012a). Cells were cultured in
differentiation medium (DMEM/F-12 (1:1) with GlutaMAX I
containing 5% FBS, 1% insulin transferrin and selenium, 1% sodium
pyruvate and 0.5% gentamicin [Invitrogen]) at a density of 6,000
cells/cm2. 10mMbGP and 50mg/ml ascorbic acidwere added once
the cells had reached confluence. Cells were incubated in a
humidified atmosphere (37°C, 5% CO2) and the medium was
changed every 2–3 days.
IDG-SW3 cell culture
The murine IDG-SW3 osteocytic cell line was obtained from
Dr. Lynda Bonewald (University of Missouri-Kansas City). Cells
were plated at 1 104 cells/cm2 inmulti-well plates and cultured as
previously described (Woo et al., 2011). Inhibitors were added to
cultures at day 0 (confluency).
Over-expression of E11 by MLO-A5 transfection
E11 was amplified from MLO-A5 cDNA- using primers designed to
flank the E11 open reading frame (forward 50-AGCTCGTTTAGT
GAACCGTCAG-30, reverse 50-CCACTTGTGTAGCGCCAAGT-
30) and the following cycling conditions: 35 cycles of 92°C for 30 sec,
61°C for 60 sec and 72°C for 60 sec. The polymerase chain reaction
(PCR) product was run on a 1% agarose gel, purified and ligated into
the pCR2.1-TOPO cloning vector (Invitrogen) according to the
manufacturer’s instructions. Individual clones of transformed
XL1-Blue E. coli (Stratagene, Santa Clara) were isolated from agar
plates and the plasmid DNA sequenced to identify those containing
the E11 insert (Genepool, University of Edinburgh). The insert was
removed from the plasmid using EcoRI, ligated into the pLVX-puro
vector (Clontech, CA) and used to transform E. coli. Plasmids were
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screened by restriction digest with XhoI to identify clones which
contained the insert in the correct orientation and plasmid DNA
was amplified and extracted using the EndoFree Maxiprep kit
(Qiagen, Sussex, UK). MLO-A5 and ATDC5 cells were transfected
with E11- and empty vector-containing plasmids using Fugene HD
transfection reagent (Roche; according to manufacturer’s
instructions). Transfections were performed in triplicate and
transfected cells were positively selected in media supplemented
with 2.5mg/ml puromycin.
Effects of cysteine protease inhibitors on MLO-A5 cells
The function of cysteine proteinases in controlling MLO-A5 E11
protein levels and morphology was examined using varying
concentrations (0–100mM) of the protease inhibitors, calpastatin,
calpeptin, acetyl-l-leucyl-l-leucyl-l-norleucinal (ALLN)
(Calbiochem, CA), 2S,3S-trans-(ethoxycarbonyloxirane-2-
carbonyl)-L-leucine-(3-methylbutyl) amide (E64d) (Cayman
Chemicals, MI), and benzyloxycarbonyl-Phe-Ala-fluoromethyl
ketone (Z-FA-FMK) (Santa Cruz Biotechnology, CA). Briefly,
confluent MLO-A5 cells were treated with media supplemented
with the aforementioned inhibitors at a range of concentrations,
and then incubated at 37°C for a further 24 h. Thereafter, protein
was extracted from monolayers, as described below, for the
determination of E11 protein expression by western blotting. To
examine the effects of ALLN on cell morphology, MLO-A5 cells
were seeded at 5 104 per well in 6 well plates and cultured
overnight at 37°C before supplementation with 15mM ALLN for
an additional 48 h. Changes in cell morphology were monitored
using brightfield microscopy and quantified by counting the
number of cells (n¼ 100 randomly selected) in triplicate cultures,
displaying projections longer than 25mm.
Effects of proteasome inhibitors on MLO-A5 and primary
osteoblast cells
Confluent MLO-A5 cell cultures were treated with media
supplemented with 0–10mM N-(benzyloxycarbonyl)-Leu-Leu-
Leucinal (MG132), lactacystin (Cayman Chemicals), Bortezomib
(Velcade1) (Santa Cruz), and Withaferin-A (Abcam, Cambridge
UK) and then incubated at 37°C for 24 h. Confluent primary cell
cultures were treated with media supplemented with ALLN,
MG132, and lactacystin. Thereafter, protein/RNA was extracted
from monolayers, as described below, for the determination of
E11 protein/mRNA expression.
Effects on RhoA/ROCK pathway in MLO-A5 cells
MLO-A5 cells were cultured in the presence of increasing
concentrations of the ROCK inhibitors, Y27632 (0–50mM;
Cambridge Bioscience) or the more potent H-1152, (0–50mM;
Cambridge Bioscience) and protein expression levels examined
by western blotting. MLO-A5 cells were treated with H-1152
in the presence/absence of ALLN for 48 h. Changes in cell
morphology were monitored using brightfield microscopy and
quantified by counting the number of cells (among n¼ 100
randomly selected) in triplicate cultures, displaying projections
longer than 25mm.
RNAextraction andquantitative real-timePCR(RT-qPCR)
Total RNA was extracted from MLO-A5 cells using Tri-Reagent
according to the manufacturer’s instructions. RNA samples were
reverse-transcribed into cDNA using Superscipt II reverse
transcriptase (Invitrogen) according to the manufacturer’s
instructions. RT-qPCR was carried out in a Stratagene Mx3000P
cycler with each reaction containing 50ng template DNA,
250nM forward and reverse primers (Primer Design,
Southampton UK) (E11: F- CTAACCACCACTCCCACTT,
R- CCAATAGACTCCAACCTGAAGA; Gapdh: sequences not
available) and PrecisionPlus Mastermix (Primer Design). The Ct
values for the samples were normalised to that of Gapdh and the
relative expression was calculated using the DDCt method (Livak
and Schmittgen, 2001). The amplification efficiencies of all the
primers were between 90–100%.
Western blotting
Protein lysates were extracted and concentrations were
determined using the DC assay (Bio-Rad, Hemel Hempstead, UK)
and 15mg of protein was separated using a 10% bis-tris gel and then
transferred to a nitrocellulose membrane and probed with goat
anti-mouse E11 (1:1000, R&D Systems) and HRP-linked rabbit
anti-goat secondary antibody (1:3,000, Dako, Cambridge, UK); or
rabbit anti-mouse proteasome subunit beta type-5 (PSMB5)
(1:1,000, Abcam) and HRP-linked goat anti-rabbit secondary
antibody (1:3,000, Dako); or rabbit anti-mouse RhoA (1:1,000, Cell
signaling) and HRP-linked goat anti-rabbit secondary antibody
(1:3,000, Dako) diluted in 5% non-fat milk. Rabbit anti-mouse ERM
and phospho-ERM (1:1000, Invitrogen) antibodies and HRP-linked
goat anti-rabbit secondary antibody (1:3,000, Dako) were diluted
in 3% bovine serum albumin.
Immune complexes were visualised by chemiluminescence
using the ECL detection kit and ECL film (GE Healthcare,
Amersham, UK). HRP-conjugated anti b-actin antibody (1:25,000,
Sigma) was used as a loading control.
RhoA activity assay
Protein was extracted fromMLO-A5 cultures and RhoA activation
measured by the GLISA assay (Cytoskeleton, Denver), which
specifically recognises active GTP-bound RhoA. The quantity of
GTP-bound RhoA was then measured by luminometry and
expressed in relative light units (RLU).
Proteasome activity
Protein lysates were extracted fromMLO-A5 cells in 0.5%NP40 at
days 0, 3, 7, 10, and 14 of culture. A proteasome activity kit
(Abcam), which takes advantage of the chymotrypsin-like activity
of the proteasome, was used according to the manufacturer’s
instructions. The kit utilises an aminomethylcoumarin (AMC)-
tagged peptide substrate which releases free, highly fluorescent
AMC in the presence of proteolytic activity. Fluorescence was
measured with a microtiter plate reader in real time for 30–60min
at Ex/Em¼ 350/440 nm at 37°C. Proteasome activity was
subsequently calculated according to the manufacturer’s
instructions.
Isolation and analysis of ubiquitinylated proteins
Protein lysates were extracted from MLO-A5 cells in 50mM
HEPES, pH 7.6, 1mM DTT and samples were diluted to
25mg/100ml. Ubiquitinylated proteins were extracted using the
UbiQapture
1
-Q kit (Enzo Life Sciences, Exeter, UK) according to
the manufacturer’s instructions. Extracted ubiquitinylated
proteins (bound fraction), as well as non-ubiquitinylated proteins
(unbound fraction), were separated using a 10% bis-tris gel and
western blotting was conducted for E11 protein as detailed above.
Statistical analysis
Data are expressed as the mean standard error of the mean (S.E.
M) of at least three replicates per experiment. Statistical analysis
was performed by Student’s t-test, one way analysis of variance
(ANOVA) or a suitable non-parametric test. P< 0.05 was
considered to be significant and noted as P values of <0.01 and
<0.001 were noted as “” and “” respectively.
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Results
E11 expression increases during osteocyte differentiation
Our previous studies indicated that extracellular matrix (ECM)
mineralization promotes E11 expression and drives osteocytic
differentiation (Prideaux et al., 2012). To more closely examine
the relationship between E11 expression and osteocytogenesis,
we examined spatial patterns of E11 protein expression during
various stages of osteoblast-to-osteocyte transition in vivo.
Immunohistochemical examination of tibia sections from
8-week-old mice disclosed that E11 protein was detected in
young, recently transitioned osteocytes close to the periosteum
(Fig. 1A and B). We also observed that osteocyte processes
connecting the young osteocytes to surface osteoblasts were
labelled positively for E11 protein whereas osteoblasts on the
bone surface and more mature osteocytes deeper within the
cortical bone matrix were devoid of labelling for E11 protein
(Fig. 1A and B). Consistent with this, immunolabelling for
sclerostin, a known marker of the late osteocyte phenotype
revealed expression in the mature osteocytes which was not
observed in the young osteocytes close to the periosteum
(Fig. 1C and D).
Whilst these observations further strengthen the link
between E11 expression and the transition from osteoblast into
the osteocyte phenotype, they do not inform their dynamic
relationship. We therefore examined E11 mRNA and protein
expression in MLO-A5 cells (late osteoblast/pre-osteocytic
cells) cultured under mineralizing conditions to promote their
osteocytic differentiation. These studies revealed that the levels
of E11 mRNA increased significantly between days 0 and 6
(P< 0.05), and continued to do so throughout the culture
period to day 10 of culture (P< 0.001) (Fig. 1E). Similar
increases in E11 protein expression were also observed
(Fig. 1F). These results are consistent with our previous data
highlighting the potent up-regulation of E11 during the
osteoblast-to-osteocyte transition (Prideaux et al., 2012).
Lack of E11 protein over-expression despite elevated
mRNA levels in transfected MLO-A5 cells
Such spatial and temporal association between increases in E11
expression and acquisition of osteocyte phenotype does not,
however, necessarily indicate a causal relationship. To provide
more direct functional evidence that E11 expression might
control the phenotypic changes taking place during osteoblast-
to-osteocyte transition, we generated an in vitro system in
which E11 gain-of-function could be engendered in MLO-A5
cells by transfection, and subsequent mRNA and protein levels
assessed by RT-qPCR and western blotting, respectively.
We found that transfection of MLO-A5 cells with E11-
containing plasmids produced 2.5-fold increases in E11 mRNA
levels when compared to cells transfected with empty vector
(Fig. 1G).We subsequently sought to confirm such E11 gain-of-
function by measuring increases in E11 protein levels in these
cells. Intriguingly, western blotting failed to detect any
significant elevation in E11 protein levels in MLO-A5 cells that
were transfected with the E11-containing plasmid (Fig. 1H). To
examine the possibility that high endogenous E11 levels may
limit the transfection-related increases in expression in MLO-
A5 cells, we also examined E11 transfection efficiency in
chondrogenic ATDC5 cells in which E11 is not constitutively
expressed. Western blotting similarly failed to detect any
significant expression of E11 protein in ATDC5 cells
transfected with the E11-containing plasmid (Fig. 1H), despite
substantial increases in mRNA expression in these transfected
cells (Fig. 1I). These data indicate lack of correlative increases in
E11 mRNA and protein levels and therefore suggest that E11
protein is inherently unstable or selectively targeted, post-
translationally, for degradation.
E11 protein is post-translationally regulated in MLO-A5
cells and this limits acquisition of osteocyte phenotype
achieved via E11
It has previously been suggested that E11 is degraded by the
calpain family of cysteine proteinases (Martin-Villar et al.,
2009). Therefore, to investigate whether the E11 protein is
similarly degraded by this family of proteases in MLO-A5 cells,
cultures were supplemented with varying concentrations of
the calpain inhibitors, calpeptin, E64d, Z-FA-FMK, and ALLN.
These studies revealed that increasing concentrations of E64d
failed to increase E11 protein expression in MLO-A5
osteoblast cells (Fig. 2A). Similarly, only modest increases in
E11 protein levels were seen in MLO-A5 cells treated with
Z-FA-FMK and calpeptin (Fig. 2B and C). However, in contrast,
ALLN produced stark and dose-dependent increases in E11
protein levels (Fig. 2D).
Furthermore, when we examined changes in MLO-A5 cell
morphology we found that in addition to producing marked
increases in levels of E11 protein, ALLN also induced a
profound elongated dendritic-like morphology in MLO-A5
cells, with some cell processes extending from the cell body to
over 100mm in length, consistent with the dendritic processes
seen in osteocytes (Fig. 2E). This is in contrast to MLO-A5 cells
supplemented with vehicle alone (ethanol) which displayed a
standard morphology, with numerous small cellular
projections (Fig. 2F). Similarly, cells treated with 10mM
calpeptin did not exhibit any differences in morphology in
comparison to control cultures (Fig. 2H and I). Quantification
of cells displaying an elongated dendritic-like morphology
showed that their percentage among ALLN-treated cells was
significantly increased (77%, P< 0.001) compared to control
cultures (27%) (Fig. 2G). These data suggest that inhibition of
E11 breakdown increases acquisition of the osteocyte
phenotype.
Consistent with the possibility that E11 is targeted for post-
translational degradation by mechanisms sensitive to ALLN,
addition of 15mM ALLN to MLO-A5 cells transfected with
empty vector now resulted in strong and robust expression of
E11 protein (Fig. 2J). Relatively modest further increases in E11
protein levels were observed in MLO-A5 cells transfected with
the E11-containing vector, consistent with the previously
detected 2.5-fold increase in E11 mRNA expression (Fig. 1G).
Treatment of the murine osteocytic cell line IDG-SW3 (Woo
et al., 2011), with ALLN also showed modestly increased E11
protein expression upon western blotting with low
concentrations of ALLN (Fig. 2K) and extensive dendrite
formation (Fig. 2L and M).
Together these data suggest that E11 protein is subject to
active, constitutive degradation via ALLN-sensitive pathways in
MLO-A5 and IDG-SW3 cells, and that blockade of these
pathways correlates with enhanced osteocyte cell
differentiation.
Calpain 1 and 2 are unlikely to be involved in regulating
E11 protein expression during MLO-A5 differentiation
Based on published data demonstrating that calpains can
degrade E11 in vitro, we speculated that the observed potent
effects of ALLN on E11 protein levels in MLO-A5 cells were
likely dependent on the inhibition of calpain activity (Martin-
Villar et al., 2009).
We explored this possibility by monitoring E11 protein levels
in MLO-A5 cells following addition of the physiological calpain-
specific inhibitor, calpastatin and found that, unlike ALLN, this
failed to promote increases in E11 protein levels (Fig. 3A).
Western blotting of lysates from differentiating MLO-A5 cells
also indicated that the protein expression levels of calpain I and II
were unchangedat all time-points (Fig. 3B andC).Together,with
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Fig. 1. E11 expression increases during osteocyte differentiation. (A) Immunohistochemical staining for E11 protein expression in 8-week-old
wild-type mouse tibia. (B) Expression was localised to young osteocytes (arrows) and their processes (arrows). Mature osteocytes were devoid
of E11 expression (arrowhead, B). (C and D) Labelling for sclerostin expression was observed in mature osteocytes (arrowheads) but not in
the young osteocytes close to the periosteum (arrows). Scale bars are 100mm (A and C), and 25mm (B and D). Results are representative of
five individual mice. (E) RT-qPCR analysis of E11 mRNA expression in mineralizing MLO-A5 cells over a 10 day culture period. Data are
represented as meanS.E.M of three individual cultures. P< 0.05, P< 0.001 in comparison to day 0. (F) Western blotting for E11 protein
expression in MLO-A5 cells over a 12 day culture period. (G) RT-qPCR for E11 mRNA in MLO-A5 cells transfected with E11 overexpressing
vectors (E11pLVX) and control cultures (pLVX). (H) Western blotting of E11 protein upon overexpression in MLO-A5 cells (E11pLVX) at
day 0 in comparison to control cultures (pLVX). Also displayed is E11pLVX and pLVX in the chondrocytic ATDC5 cell line, and in MLO-A5
control cultures (i.e. non-transfected cells) at day 15 of culture. (I) E11 mRNA expression by RT-qPCR in E11pLVX and pLVX transfected
ATDC5 cells. Data are represented as meanS.E.M of three individual cultures. P< 0.05, or P< 0.001, in comparison to control cultures
(pLVX) at day 0.
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Fig. 2. Western blotting of E11 protein (38 kDa) expression in MLO-A5 cells treated with increasing concentrations of (A) E64d,
(B) Z-FA-FMK, (C) Calpeptin, (D) ALLN, for 24 h. b-actin was used as a loading control. Effect of ALLN treatment on MLO-A5 cell
morphology after 48 h with (E) 10mM ALLN and (F) 0mM ALLN treatment. Control cultures display numerous short cell projections
(arrowheads, F) in comparison to treated cells which display multiple long, thin cytoplasmic cellular projections (arrows, E). (G) The
percentage of MLO-A5 cells expressing an elongated dendritic-like morphology after treatment with ALLN in comparison to control
cultures. Data are represented as meanS.E.M of three individual experiments. P< 0.01 in comparison to control cultures. Effect of
calpeptin treatment on MLO-A5 cell morphology after 48 h with (H) 10mM calpeptin (I) 10mM calpeptin; both control and calpeptin-
treated cells displayed short, cell projections (arrowheads). (J) Overexpression of E11 in MLO-A5 cells upon addition of 15mM ALLN
(E11pLVX) at day 0 for 24 h, in comparison to control cultures treated with 15mM ALLN (pLVX). (K) Western blotting of E11 protein
(38 kDa) expression in IDG-SW3 cells treated with increasing concentrations of ALLN. Effect of ALLN treatment on IDG-SW3 cell
morphology after 48 h 10mM ALLN treatment. Control cultures display numerous short cell projections (arrowheads, L) in comparison to
treated cells which display multiple long, thin cytoplasmic cellular projections (arrows, M). b-actin was used as a loading control.
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our previous data showing that E11 stability was influenced by
only the very highest calpeptin concentrations (Fig. 2C), these
observations suggest that calpains are unlikely to be responsible
for E11 degradation and that the effects observed upon addition
of ALLN are likely via alternative mechanisms.
Levels of E11 are regulated via proteasome pathways
during osteocytogenesis in MLO-A5 cells
As well as having inhibitory effects on calpains and cathepsins,
ALLN is also capable of exerting inhibition of proteasome-
mediated protein degradation, as are calpeptin and Z-FA-FMK
which also stimulated modest E11 protein increases (Giguere
and Schnellmann, 2008). Therefore to examine whether the
proteolytic mechanism underpinning E11 stability resides
within the proteasome, we sought to determine the effect of
the specific proteasome inhibitors lactacystin and MG132 on
MLO-A5 E11 protein expression.
Addition of both MG132 and lactacystin resulted in a
dramatic increase in E11 protein expression levels within 24 h.
Enhanced E11 protein levels were noticeable at concentrations
of lactacystin and MG132 as low as 10mM and 1mM,
respectively (Fig. 4A and B), comparable with those achieved
upon 100mM ALLN treatment (Fig. 4C). Similar increases in
E11 mRNA were observed in MLO-A5 cells upon addition of
the inhibitors ALLN, MG132, and lactacystin for 24 h (Fig. 4D).
However, increased transcription upon treatment with
proteasome inhibitors has previously been reported in differing
cell types suggesting an additional mechanism by which the
proteasome may function in osteocytes (Butler et al., 2009;
Rockwell and Qureshi, 2010).
Increases in E11 protein expression were also observed
in primary osteoblast cells treated with increasing
concentrations of ALLN, MG132, and lactacystin (Fig. 4E)
once they had reached confluency. The expression of E11 in
these cultures at this early time point has been reported
in previous studies by us and others (Zhang et al., 2006;
Prideaux et al., 2012). Furthermore, addition of the
proteasome inhibitor Bortezomib also induced a dose-
dependent increase in E11 protein expression after 24 h
(Fig. 4F). Increases in E11 protein expression above control
levels were also observed in
MLO-A5 cells upon addition of Withaferin A, a proteasome
inhibitor isolated from Withania somnifera (Fig. 4G).
These data strongly implicate proteasome degradation,
rather than cysteine proteases in controlling E11 stability and
hence levels. We next examined whether this process of E11
protein stabilization was active at all stages of osteoblast-to-
osteocyte transition, by evaluating the effects of these selected
proteasome inhibitors on E11 levels at various time points
during MLO-A5 cell osteocytic differentiation. Western
blotting revealed that E11 protein is indeed increased by
MG132 (Fig. 5A) and by Bortezomib (Fig. 5B) at all stages of
MLO-A5 cell differentiation.
The increased levels of E11 protein at osteoblast-to-
osteocyte transition suggest an endogenous control of
proteasome activity in these osteocyte cells. We therefore
examined proteasome activity throughout MLO-A5 cell
differentiation and found it to be significantly decreased from
day 7 of culture (P< 0.01 in comparison to day 0). Proteasome
activity continued to be decreased at later stages of culture
(P< 0.01 and P< 0.05 at days 10 and 14, respectively, in
comparison to day 0) (Fig. 5C). Furthermore, our results
revealed a trend towards decreased expression (from day 7
onwards) of PSMB5 protein, the major proteasome subunit,
(Fig. 5D) withMLO-A5 cell osteocytogenesis. Finally, to further
confirm our findings we used immunoprecipitation to isolate all
ubiquitinylated proteins and found E11 to be among the
proteins expressed in the ubiquitinylated form at both days 0
and 7 of MLO-A5 cell culture (Fig. 5E). Furthermore, as
expected, ubiquitinylated E11 protein levels were increased
upon addition of the proteasome inhibitors MG132 and
Bortezomib at both these time points (Fig. 5E).
E11 stabilization promotes osteocyte differentiation
through RhoA
To investigate the mechanisms by which E11 stabilization
promotes osteocyte differentiation, we examined the role of
the RhoA/ROCK/ERM pathway. In MLO-A5 cells, we found
that RhoA levels were unchanged throughout the culture
period (Fig. 6A). Interestingly, RhoA activation (GTP-bound
RhoA) was however increased in MLO-A5 cells from day 3 of
culture, concurrent with cell differentiation and matrix
mineralization, in a pattern which mimicked E11 expression
(Fig. 6B). Similarly, stabilization of E11 through the
administration of proteasome inhibitors also increased RhoA
activity (13–26% in comparison to control cultures) further
suggesting that E11 acts to promote osteocytogenesis through
this pathway.
To further interrogate the role of this pathway in E11-
mediated osteocytogenesis, we cultured MLO-A5 cells in the
presence of the ROCK inhibitor Y27632 (Martin-Villar et al.,
2006). Unexpectedly, increasing concentrations of Y27632 did
not alter phosphorylation of the ROCK downstream target
ERM, in MLO-A5 cells (Fig. 6C), nor did the more potent
ROCK inhibitor H-1152 (Fig. 6D).
Examination of cell morphology in MLO-A5 cells treated
with H-1152, revealed a flattened cell shape without
discernible processes (Fig. 6G) in comparison to those treated
Fig. 3. (A)Western blotting of E11 protein (38 kDa) expression in
MLO-A5 cells treated with 15mM ALLN and 100mM calpastatin.
Western blotting of (B) calpain I and (C) calpain II protein in
mineralising MLO-A5 cells over a 15-day culture period. b-actin was
used as a loading control.
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with 10mM ALLN (Fig. 6F) which, as before, showed marked
elongated dendritic-like cell morphology compared to vehicle-
treated controls (Fig. 6E). Intriguingly, MLO-A5 cells treated
with a combination of ALLN and H-1152 in contrast showed
very dramatic alterations in cell phenotype with strikingly long
and elaborate processes (Fig. 6H); quantification confirmed
significant increases compared to both control (P< 0.001) and
ALLN treated cultures (P< 0.05) (Fig. 6I). Similarly, high
H-1152 (50mM) concentrations combined with ALLN
increased phosphorylation of ERM protein, in comparison to
cultures treated with 10mM ALLN alone (Fig. 6J). Similar
results were observed with cells treated with both H-1152 and
10mM MG132 or 10mM Bortezomib (Fig. 6J). Together with
previous data these findings suggest that osteocytogenesis
involves E11-mediated RhoA activation that is dependent upon
the inhibition of the proteasome in late, pre-osteocytic,
osteoblasts.
Discussion
Our studies have shown for the first time that E11/podoplanin
is a short-lived protein and that mechanisms reliant on the
blockade of proteasome-mediated E11 destabilization
contribute to the osteocytogenic recruitment of bone cells.
Our data show the potent up-regulation of E11 during the
osteoblast-to-osteocyte transition, suggestive of E11 playing a
critical role in early osteocyte differentiation as has previously
been described by us, and others (Nefussi et al., 1991;
Barragan-Adjemian et al., 2006; Zhang et al., 2006; Prideaux
et al., 2012 Dallas et al., 2013). We have previously shown that
E11 is also intimately regulated by the ECM mineralization
status (Prideaux et al., 2012). Here we have complemented this
with clear evidence that induction of E11 protein expression in
undifferentiated cells results in dendrite formation and
elongation. The osteocyte process network is vital for
Fig. 4. Western blotting of E11 protein (38 kDa) expression in MLO-A5 cells treated with 0mM, 0.1mM, 1mM, and 10mM of (A) Lactacystin
(B) MG132 for 24h. b-actin was used as a loading control. (C) Western blotting of E11 protein (38 kDa) expression in MLO-A5 cells treated
with 100mM ALLN, 10mM MG132 and 10mM lactacystin for 24h. b-actin was used as a loading control. (D) RT-qPCR analysis of E11 mRNA
expression in MLO-A5 cultures following addition of 100mM ALLN, 10mM MG132, and 10mM lactacystin for 24h. Data are represented as
meanS.E.M of three individual cultures. P< 0.01 in comparison to control cultures. (E) Western blotting of E11 protein (38 kDa)
expression in primary osteoblast cells treated with 0, 0.1, 1, and 10mM of ALLN, lactacystin and MG132 for 24h. b-actin was used as a loading
control. Western blotting of E11 protein (38 kDa) expression in MLO-A5 cells treated with 0, 0.1, 1, and 10mM of (F) Bortezomib (G)
Withaferin A for 24h. b-actin was used as a loading control.
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maintaining cell viability and allowing the transfer of nutrients
and waste products between osteocytes buried deep in the
bone and the circulatory network (Bonewald, 2012). These
results therefore suggest that E11 plays an important role
during osteocyte formation. These data are consistent with a
recent publication detailing the role of E11 in invadopodia
stabilization and maturation in squamous cell carcinomas
(Martin-Villar et al., 2014).
To further delineate this mechanistic role, we examined the
morphological effects of E11 gain-of-function in MLO-A5 cells.
Surprisingly, however, although we could show increases in
E11 mRNA in suitably transfected MLO-A5 cells, this did not
produce concomitant increases in E11 protein expression. This
lack of correlation between E11 protein and mRNA levels was
more pronounced in the ATDC5 chondrocyte cell line where
basal E11 levels were negligible. We appreciate that as no E11
protein expression is observed in the empty-vector
transfected cultures at day 0, it may be viewed that there is no
capability for the MLO-A5 cells to overexpress E11 at this time
point. However our data, combined with the lack of E11
protein in undifferentiated MLO-A5 cells, which express E11
mRNA, indicate profound post-transcriptional and/or post-
translational regulation of E11 protein levels.
E11 has previously been shown to be a substrate for the
neutral cysteine proteinase, calpain II, with many different
tumour cell lines expressing high levels of E11 mRNA but not
E11 protein (Martin-Villar et al., 2009). We report here that
specific inhibition of calpain activity using the endogenous
inhibitor calpastatin did not result in an accumulation of E11
protein in MLO-A5 cells. An amplifying effect was observed,
however, on both E11 protein levels and osteocyte dendrite
formation using the inhibitor ALLN. This is strong, albeit
indirect evidence that elevated levels of E11 are pivotal for the
formation of osteocyte dendritic projections and extends
Fig. 5. Western blotting of E11 protein (38 kDa) expression in MLO-A5 cells treated with 10mM of (A) MG132 (B) Bortezomib for 24h
prior to each time point over a 14 day culture period. b-actin was used as a loading control. (C) Proteasome activity in MLO-A5 cells over a
14 day culture period. Data are represented as meanS.E.M of three individual cultures. P< 0.05, P< 0.01 in comparison to day 0. (D)
Western blotting of PSMB5 (25 kDa) expression in MLO-A5 cells over a 14 day culture period. b-actin was used as a loading control.
(E) Immunoprecipitation of all ubiquitinylated proteins identified E11 to be expressed at both days 0 and 7 of MLO-A5 cell culture,
both addition of 10mM MG132/Bortezomib. Data are represented as meanS.E.M.
JOURNAL OF CELLULAR PHYSIOLOGY
P R O T E A S O M E I N H I B I T I O N I N C R E A S E S E 1 1 S T A B I L I T Y 9
previous studies in which dendrite formation was shown to be
blocked by E11 siRNA (Zhang et al., 2006).
ALLN is a cell-permeable inhibitor of calpains I and II, which
is known to inhibit cathepsins B and L, and the proteasome.
Here we identified the proteasome as the specific target of
ALLN in MLO-A5 cells through examination of the effects of a
range of other proteases and proteasome inhibitors on E11 and
ubiquitin levels. This result is contradictory to that observed by
Martin-Villar et al., in tumour cell lines whereby they used
ALLN, MG132, calpeptin and lactacystin and showed that
calpeptin displayed the greatest effect, whilst ALLN andMG132
induced only modest increases in E11 protein expression
(Martin-Villar et al., 2009). The very elegant studies of Martin-
Villar et al., also report that lactacystin had no effect on E11
expression. On this basis, the authors infer that calpains
regulate E11 expression in this cell line. Whilst calpeptin is
generally considered as a calpain inhibitor, like ALLN and
MG132 it also has inhibitory effects on the proteasome
(Giguere and Schnellmann, 2008) and as our differing
conclusions may be due to different considerations of inhibitor
specificity and/or suggests that E11 may be subject to
differential regulatory mechanisms dependent upon cell type
(Martin-Villar et al., 2009). It also highlights that E11 stability
may vary in different circumstances and that this is an important
Fig. 6. (A) Western blotting of RhoA protein expression in MLO-A5 cells over a 15 days culture period. b-actin was used as a loading control.
(B)Quantification ofGTP-boundRhoA (RhoAactivity) inMLO-A5 cells over a 15 days culture period. Data are representative of two independent
experiments. P< 0.001 in comparison to day 0. (C)QuantificationofGTP-boundRhoA (RhoAactivity) inMLO-A5 cells over treatedwith 10mM
ALLN, 10mMMG132 and 10mMBortezomib for 24h. Data are represented asmeanS.E.M of three individual cultures in duplicate (D)Western
blotting of phosphorylatedERM (80kda) and total ERM (75kDa) inMLO-A5cells cultured in thepresence of 0, 5, 10, and 50mMY27632.b-actin
was used as a loading control. (E) Western blotting of phosphorylated ERM (80kda) and total ERM (75kDa) in MLO-A5 cells cultured in the
presence of 0, 1, 10, and 50mMH-1152. b-actin was used as a loading control. Effect of H-1152 and ALLN treatment on MLO-A5 cell morphology
after 48hwith (F) vehicle treated, (G) 10mMALLNtreatment (H) 10mMH-1152 (I) 10mMH-1152 and10mMALLNtreatment. (J)The percentage
of MLO-A5 cells expressing an elongated dendritic-like morphology after treatment with ALLN, H-1152, and ALLN & H-1152 in comparison to
control cultures.Data are represented asmeanS.E.Mof three individual experiments. P< 0.01, P< 0.001 in comparison to control cultures.
(K)Western blotting of phosphorylated ERM (80kda) and total ERM (75kDa) in MLO-A5 cells cultured in the presence of 0, 1, 10, and 50mM
H-1152 with 10mM ALLN or MG132 or Bortezomib. b-actin was used as a loading control.
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consideration should it ever be identified as a therapeutic
target. Nevertheless, we observed similar results to our
MLO-A5 data in both primary calvaria osteoblasts and the late
osteoblast-osteocytic IDG-SW3 cell line, thus providing
further evidence that the proteasome plays the critical role in
E11 regulation in osteoblasts.
The ubiquitin-proteasome system functions to degrade
regulatory and abnormal proteins. As such, proteasome
activity, conferred by six catalytic active sites which have
chymotrypsin-like, trypsin-like, and caspase-like activities, is
tightly regulated and attuned to cellular requirements. Here we
reveal decreased proteasome activity uponMLO-A5 osteocyte
cell differentiation. Indeed, it is already well known that the
ubiquitin-proteasome pathway exerts exquisite control of
osteoblast differentiation, with administration of proteasome
inhibitors increasing bone volume and bone formation rates
(Garrett et al., 2003). As such, it is possible that our observed
decreases in proteasome activity during MLO-A5 cell
osteocytogenesis may explain the concomitant increases in E11
protein expression, and for the first time point to a critical role
for the proteasome in regulating osteocyte differentiation.
Whether stabilizing E11 increases sclerostin levels in
concordance with promotion of osteocytogenesis is an
interesting consideration, however, not one examined here
due to the negligible levels of sclerostin produced both at the
mRNA and protein level in MLO-A5 cells (Kato et al., 2001).
Also, sclerostin is amarker of the late osteocyte (Winkler et al.,
2003) and as our results here are promoting differentiation of
osteoblasts into immature osteocytes, we do not think that the
24 h time period is enough to push the cells into a more mature
sclerostin-expressing osteocyte phenotype. Osteocyte
function is known to be tightly linked to the Wnt/b-catenin
signaling pathway. Since key components of this pathway, such
as b-catenin, as well as those of other crucial pathways in bone,
including NF-kB, are known to be regulated by proteasomal
turnover, it is possible that this new proposed key role for the
proteasome in osteocyte form and function may be more
extensive (Gaur et al., 2005; Skaug et al., 2009). Indeed whilst
our data here suggests E11 to be the likely candidate, it is
possible that other mechanisms may be involved which again,
must be considered should E11 stabilization be pursued as a
therapeutic target.
One of the most potent promoters of E11 protein levels
observed herein was Bortezomib. Bortezomib, a peptide
boronic acid congener, directly inhibits the chymotrypsin-like
activity of the proteasome PSMB5 subunit and is used for the
treatment ofmultiple myeloma; it is also undergoing clinical trials
for the treatment of several epithelial cancers (Ria et al., 2014).
Bone disease occurs in up to 80% of patients with multiple
myeloma and is characterised by an imbalance in bone
remodelling towards increased osteoclastic bone resorption
(Qiang et al., 2012). Proteasome inhibition in patients with
multiple myeloma has an anabolic effect on bone formation
(Garrett et al., 2003; Zangari et al., 2005; Terpos et al., 2007),
thought to be through its effects on b-catenin and the NF-kB
pathway (Qiang et al., 2009). Bortezomib also increases
osteogenic differentiation and bone formation in mesenchymal
stem cells and C2C12 cells, highlighting its potential as a
therapeutic agent for other diseases of bone loss (Giuliani et al.,
2007; Uyama et al., 2012; Sanvoranart et al., 2014). Whether
these anabolic effects of proteasome inhibitors on bone
formation are through stabilization of E11 is yet to be
determined. It would be of particular interest to investigate bone
morphology in E11 nullmice treatedwith proteasome inhibitors.
Such mice are however embryonically lethal (Zhang et al., 2006),
and as such themost revealing studieswould be those conducted
in an osteocyte specific conditional E11 knockout mouse.
As well as the observed increase in E11 protein expression,
we also revealed that Bortezomib/ALLN/MG132 increased
E11 mRNA levels. In other studies MG132 and Bortezomib
have been reported to induce mRNA increases through both
transcriptional (promoter activation) and post-transcriptional
(mRNA stability) mechanisms (Butler et al., 2009; Laroia et al.,
1999; Shimizu et al., 2013). Conversely, MG132 causes
defective polyadenylation (Lee and Moore, 2014) and whilst it
has been previously shown that in human tissues, there is a
2.7 kb and a 0.9 kb E11 mRNA species, which differ in their
polyadenylation (Martin-Villar et al., 2009), there is no
suggestion that this is the case in murine tissues. It would be
interesting however to examine whether the stabilization of
E11 observed here is maintained upon addition of a protein
synthesis inhibitor, such as cycloheximide. However, the
known off target effects of such a pharmacological agent are
sufficient to render the merits of such experimentation
questionable. Similarly, it would be interesting to do
knockdown studies of E11 in proteasome inhibitor treated
cells, however our numerous efforts using several
commercially available siRNA constructs have allowed us only
to partially knockdown E11 and as such, the residual E11 would
make it very difficult to interpret any resultant data.
Ubiquitin is conjugated to proteins that are destined for
proteasome-mediated degradation by three broadly expressed
enzymes: (1) ubiquitin-activating enzyme (E1), (2) ubiquitin-
conjugating enzyme (E2), and (3) ubiquitin ligase (E3). In bone,
runt-related transcription factor 2 (RUNX2) is known to be
tightly controlled by the proteasome through the E3 ubiquitin
ligases Smad ubiquitin regulatory factor -1 (Smurf-1), Smurf-2
and WW-domain-containing protein 1 (WWP1) (Zhao et al.,
2003, 2004). Here, immunoprecipitation demonstrated that
E11 is also ubiquitinated in MLO-A5 cells. We also show the
increased expression of ubiquitinated-E11 upon treatment of
cells with MG132 and Bortezomib. E11 is a hydrophobic
transmembrane protein in which O-glycosylation confers
resistance to proteolytic degradation; indeed blockade of O-
glycosylation in endothelial cells markedly diminishes E11 levels
and intriguingly phenocopies the global E11/ embryonic
mouse (Fu et al., 2008). Indeed it is well recognised that protein
ubiquitination is modulated by glycosylation (Roos-Mattjus and
Sistonen, 2004; Butkinaree et al., 2010) and as such, this raises
the possibility that E11 glycosylation enhances E11 stability in
pre-osteocytes; a possibility that is currently being explored.
To further delineate the mechanisms by which stabilization
of E11 promotes osteocyte differentiation, we have
investigated potential downstream signaling and function,
namely the RhoA pathway. RhoA is a small GTPase and a
master regulator of various cellular processes such as
cytokinetics, cytoskeletal regulation, and cell migration (Takai
et al., 2001). In addition to osteocytes, E11 has also been
detected in many other cells and it was in one of these cell
types, MDCK, that E11 was first demonstrated to regulate
RhoA signaling (Martin-Villar et al., 2006). Activation of RhoA
by E11 was required for the formation of cell protrusions and
invasion of the cells through amatrigel substrate. To investigate
whether E11 was able to activate RhoA in MLO-A5 cells it was
first necessary to examine small GTPase expression in this cell
line. RhoA protein was detected at all stages of MLO-A5 cell
differentiation and its activation (GTP-bound RhoA) was
increased in MLO-A5 cells from day 3 of culture. This pattern
mimicked that of E11, osteocyte differentiation and matrix
mineralization in these cells. This suggests a link between E11
expression and increased activation of RhoA in MLO-A5 cells,
similar to those previously observed in MDCK cells. It also
suggests that RhoA activation may be required for
osteocytogenesis, as was further indicated by the increased
RhoA activity observed upon E11 stablization. The role of
RhoA signaling during osteoblast differentiation is however a
contentious issue, with studies describing both a positive
(McBeath et al., 2004; Meyers et al., 2005; Arnsdorf et al., 2009;
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Khatiwala et al., 2009) and negative (Harmey et al., 2004;
Kanazawa et al., 2009) effect of RhoA activation on osteoblast
differentiation.
RhoA has many downstream effectors including ROCK
which has been shown to be important in the cytoskeletal
changes observed in podoplanin induced MDCK cell epithelial-
mesenchymal transitions (Martin-Villar et al., 2006). Here cells
were cultured with the selective ROCK inhibitor H-1152 in the
presence (or absence) of ALLN. MLO-A5 cells cultured with
ROCK inhibitor alone displayed a flattened and spread
morphology with few processes. It would therefore be
reasonable to expect ROCK inhibition to have an antagonistic
effect on the formation of processes in response to proteasome
inhibition. The opposite was true however, as MLO-A5 cultures
supplemented with ROCK inhibitor and ALLN displayed a
particularly pronounced dendritic morphology similar, but
quantitatively more marked, than in cells treated with ALLN
alone. MLO-A5 cells from the ROCK and ALLN supplemented
cultures also projected a greater number of processes
compared to cultures treated with ALLN alone and the
processes showed a higher degree of connectivity, forming an in
vitro interconnected network of cells. The reasons for the
additive effects of both proteasome and ROCK inhibition are
unknown, but a recent study has shown that ROCK II impairs
dendrite formation and growth in neurons (Duffy et al., 2009). If
ROCK II has similar functions in osteocytes then this suggests a
possible mechanism of regulating E11-induced process
formation. This suggests that increases in RhoA signaling alone
may not be responsible for the ALLN-mediated changes in cell
structure. Another cytoskeletal protein ezrin, which is a
member of the ERM family of proteins and is essential for linkage
of the actin cytoskeleton to the plasma membrane, is also
involved in the formation of filopodia by activating RhoA and this
occurs due to binding of ezrin to specific binding sites within E11
(Scholl et al., 1999; Martin-Villar et al., 2006, 2014). This could
also provide explanation as to the increased ERM observed in
our cultures treated with both the ROCK inhibitor H-1152 and
proteasome inhibitors.
Together, these data suggest that proteasome-mediated
degradation of E11 acts to suppress Rho-mediated process
formation. Perhaps this provides evidence for a point of
integration of E11 and Rho pathways, at which multiple signals
converge to accelerate osteocytogenesis. These findings may
indicate that this osteocytogenic process also initiates
mechanisms that endogenously suppress excessive E11-related
process formation. Further experiments are required
however, before the role of RhoA and ROCK during
osteocytogenesis may be fully elucidated.
In summary, our data indicate that E11 protein is essential
for osteocyte formation, and our understanding that
proteasome-mediated E11 protein degradation limits this
acquisition of the osteocyte phenotype will offer new
insights into the process of osteocytogenesis. Considering
the use of Bortezomib in clinics, our findings in this study
warrant further investigations to determine whether
proteasome inhibitors could be used for other bone-related
diseases.
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